ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2168

Dissociation of FVC and Dlco in Patients with Dermatomyositis and Polymyositis

Eun Hye Park1, Woo Chang Hwang2, Eun Young Lee1, Eun Bong Lee1, Yeong Wook Song3 and Jin Kyun Park1, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), 2Department of Statistics, Data Science for Knowledge Creation Research Center, Seoul National University, Seoul, Korea, Republic of (South), 3Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Seoul, Korea, Republic of (South)

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Polymyositis/dermatomyositis (PM/DM) and pulmonary complications, Raynaud's phenomenon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Interstitial lung disease in patients with polymyositis (PM) and dermatomyositis (DM) is characterized by decrease in both lung compliance and pulmonary vascularity, leading to decreased forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO). However, since DLCO is also influenced by the pulmonary circulation, additional pulmonary vascular disease would disproportionally decrease DLCO. This study was aimed to investigate the changes in FVC and DLCO over time in patients with DM and PM and to identify factors associated with disproportional decline in DLCO.

Methods:

A total of 89 DM and 14 PM patients who had been cared at the Rheumatology Clinic of Seoul National University Hospital, a tertiary referral center, from January 2004 to June 2016, with 2 or more pulmonary function tests (PFTs) during follow-up duration, were retrospectively evaluated. FVC and DLCO were expressed as the percentage of values predicted on the basis of patient age, sex, height and weight. Regression was calculated using mixed model with random effect.

Results:

Total of 103 patients with DM and PM were included. The study population was predominantly female (72.8%), with the mean age at diagnosis of 49.9 ± 12.9 years. The mean duration of follow-up was 4.4 ± 3.2 years. There was a strong correlation between FVC and DLCO at baseline (r= 0.618, p<0.001). In 85 (82.5%) of 103 patients, DLCO was lower than FVC by 9.8±14.2% at baseline. There was disproportional change in DLCO relative to FVC over time. Patients with worse decline of DLCO than the change of FVC over time had a higher frequency of Raynaud’s phenomenon (35.1% vs 9.7%, p= 0.021) and positive antinuclear antibody (ANA) (78.4% vs. 48.4%, p=0.012) compared to the patients with better improvement of DLCO relative to FVC over time. There was no significant difference in other clinical and laboratory parameters according to disproportional decline in DLCO relative to FVC. Patients with Raynaud’s phenomenon had significantly higher decline of DLCO from the baseline than those without Raynaud’s phenomenon (-5.6 ± 16 vs 4.4 ± 18.4, p=0.016) and the observed changes of DLCO per year (-9.0 ± 28.3 vs 4.9 ± 29.4 p=0.040).

Conclusion:

In patients with DM and PM, Raynaud’s phenomenon and positive ANA are associated with disproportional decline in DLCO relative FVC. Further prospective studies are needed to determine whether improving pulmonary circulation adds any therapeutic benefit in those idiopathic inflammatory myopathy patients with disproportional decline in DLCO.


Disclosure: E. H. Park, None; W. C. Hwang, None; E. Y. Lee, None; E. B. Lee, Pfizer Inc, 5; Y. W. Song, None; J. K. Park, None.

To cite this abstract in AMA style:

Park EH, Hwang WC, Lee EY, Lee EB, Song YW, Park JK. Dissociation of FVC and Dlco in Patients with Dermatomyositis and Polymyositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/dissociation-of-fvc-and-dlco-in-patients-with-dermatomyositis-and-polymyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dissociation-of-fvc-and-dlco-in-patients-with-dermatomyositis-and-polymyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology